article thumbnail

Time To First Prescription Fill at Health System, External Pharmacies Reviewed

Drug Topics

Timing of treatment initiation is crucial for patients with cancer.

article thumbnail

Cap on Out-of-Pocket Insulin Costs in Inflation Reduction Act Increased Prescription Fills

Pharmacy Times

Thousands more people filled their insulin prescriptions following the introduction of the cap in January 2023, especially compared to those who were not enrolled in Medicare, a new study finds.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FTC report finds PBM power has “dire consequences”

pharmaphorum

The six largest PBMs in the US manage nearly 95% of all prescriptions filled in the US, a “concentrated market structure” that has allowed them to “profit at the expense of patients and independent pharmacists,” according to the financial regulator.

article thumbnail

Medicare Part D Claims Have Increased, But 340B Prescriptions Increased Faster

Pharmacy Times

The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% in 2013 to 19.3% to 49.9%.

article thumbnail

STAT+: Elevance PBM’s president out as customers complain of prescription chaos

STAT

Paul Marchetti, the head of insurer Elevance Health’s pharmacy benefit manager, has left the company amid a wave of consumer complaints about patients receiving incorrect medicines or being unable to get their prescriptions filled.

article thumbnail

Mark Cuban's D2C pharmacy won't beat most insured patients' out of pocket drug prices, one study finds

Fierce Healthcare

Uninsured consumers find the greatest savings, while Medicaid patients see none at all.

Insurance 111
article thumbnail

Opinion: Shortages of generic drugs can’t be blamed solely on group purchasing organizations

STAT

More than 90% of prescriptions filled that year were for generics or biosimilars, up from just over 18% the year that Hatch-Waxman was passed. The Hatch-Waxman Act of 1984, which gave rise to the modern generic drug market, was one of the most significant cost-reducing policy innovations of the last 40 years.